Business Context and Reporting Period
Company: 4D Molecular Therapeutics, Inc. (FDMT)
Filing Type: Form 8-K (Current Report)
Date: December 10, 2025
Subject: Protocol amendments to Phase 3 clinical trials for 4D-150 in wet Age-related Macular Degeneration (AMD).
Key Financial Metrics
This filing is a Current Report (Item 8.01) and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Enrollment Increase: Target enrollment for the 4FRONT-1 and 4FRONT-2 Phase 3 trials increased from 400 to 480 patients per trial.
- Regulatory Strategy: The increase is designed to provide approximately 90% power with a noninferiority margin of approximately 4 letters for regulatory agencies outside the U.S. (e.g., Japan PMDA, European EMA), while maintaining the original 4.5-letter margin for the U.S. FDA.
- Current Status: As of December 10, 2025, 4FRONT-1 has 300 patients randomized or approved to randomize. 4FRONT-2 site activation in Europe and Asia-Pacific is consistent with plans.
Guidance, Outlook, and Management Commentary
- Financial Runway: Management anticipates no impact on the previously guided financial runway into the second half of 2028.
- Enrollment Timeline:
- 4FRONT-1: Enrollment completion expected in Q1 2026; topline data disclosure expected in H1 2027.
- 4FRONT-2: Enrollment completion expected in H2 2026; topline data disclosure expected in H2 2027.
- Commercial Context: Amendments support global regulatory submissions, including for the Company's partner, Otsuka Pharmaceutical Co., Ltd., in the Asia-Pacific region.
- Risks: Forward-looking statements are subject to risks and uncertainties detailed in the Company's most recent Form 10-Q.
Investor Verification Checklist
- Verify the updated enrollment targets (480 patients per trial) in subsequent clinical trial updates.
- Confirm that the increased enrollment does not alter the projected cash burn rate or extend the financial runway beyond H2 2028.
- Monitor the progress of 4FRONT-1 enrollment to ensure the Q1 2026 completion target remains on track.
- Review the specific noninferiority margin requirements for the PMDA and EMA to understand the commercial implications of the 4-letter margin.